Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prostate Cancer Antigen-3 (PCA-3) and TMPRSS2-ERG (T2-ERG) Score Changes During Initiation of Androgen Deprivation Therapy (ADT) With Triptorelin 22.5mg in Patients With Advanced Prostate Cancer (PCA): A Phase III, Single Arm Multicentre Study

NCT01020448 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT01020448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01020448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prostate Cancer Antigen-3 (PCA-3) and TMPRSS2-ERG (T2-ERG) Score Changes During Initiation of Androgen Deprivation Therapy (ADT) With Triptorelin 22.5mg in Patients With Advanced Prostate Cancer (PCA): A Phase III, Single Arm Multicentre Study
Lead sponsor
Ipsen
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2009
Completion date
June 30, 2013
Enrollment
339 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer